PTCT PTC Therapeutics Inc.

23.93
-0.58  -2%
Previous Close 24.51
Open 24.40
Price To book 6.80
Market Cap 992845649
Shares 41,489,580
Volume 578,780
Short Ratio 5.27
Av. Daily Volume 919,218

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial has commenced - noted October 12, 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017 voted that although it is possible that ataluren may be effective, the data are inconclusive, and more work would be needed to establish whether ataluren is effective. FDA issued CRL October 25, 2017.
Ataluren
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
  2. PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
  3. Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy
  4. Data from RG7916 Programs in SMA to be Presented at the International Scientific Congress on Spinal Muscular Atrophy
  5. Drugmaker Raises U.S. Price of Muscular-Dystrophy Treatment
  6. PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%
  7. PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
  8. PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities
  9. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  10. PTC Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference
  11. PTC Therapeutics Shows Market Leadership With Jump To 84 RS Rating
  12. How Does PTC Therapeutics Inc’s (NASDAQ:PTCT) Earnings Growth Stack Up Against Industry Performance?
  13. PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : December 26, 2017
  14. Stocks With Rising Relative Strength: PTC Therapeutics
  15. Update in Lawsuit for Investors in NASDAQ:PTCT shares against PTC Therapeutics, Inc. announced by Shareholders Foundation
  16. ETFs with exposure to PTC Therapeutics, Inc. : November 29, 2017